Indy-based Acacia Pharma being acquired by New Jersey firm; fate of local operations unknown

  • Comments
  • Print
Listen to this story

Subscriber Benefit

As a subscriber you can listen to articles at work, in the car, or while you work out. Subscribe Now
This audio file is brought to you by
0:00
0:00
Loading audio file, please wait.
  • 0.25
  • 0.50
  • 0.75
  • 1.00
  • 1.25
  • 1.50
  • 1.75
  • 2.00

Please subscribe to IBJ to decode this article.

eegoope tessla.eaprrnsraio,gnrrd vgtrFduPo5v,ua u gAeppau eg inudwot re accuta aa 1cohcnyirp em rflees yednrtte lrlisidrio pshri Geqi ea rnd oyaybvdsa

euelmtnwriitevny redhdot no,sn,t leq nhhltswanhmerpos ta eaal paIhaoos icrsuhniesthd on a e aeeoam ss siah. atE ind

d aawh ttawaphdiaeg dll gn1sEremeslofn y eopln b etew. qtb f a aoe9o3yioei N .siineyi ipolirmefahosaleyrerud IiwJ,pc,rueifd emnr c0 rngekemdw hioa we mllyoeticllfac eeoiiaanhaet mytp oihibiantse,,nr oc arafNranL iace tlk itmanssi wo gjlAccPh hcnWrh ate csrs.$ ,beawtnu

dheh xdbe ont p ea2wchdrdelnamhasaT evc eecv dotrd plnlesajalun.e uymsoa uar roer,t s soeon eitp 8ca cnMogtr nmlen eaisr

ene o s ii orlni pu SihaiBre0adnsnrP .,rio>n1so.i 2nwish oltcun ai8e asentpoi sa,/gott7pRe acntcekln Irnneteo fwcd Efbiesm rdohe

mtadtl, ecgtcesinrssasuKtapfmicd hce au&mnkiit wooye ha fl ;Dd egieorpn teowal ssro l a pedraamtsrvm nIcpso tRrth e oalo eehmnn .Tessoiu .tohnr hdo Uo

uoesoon se sio’ otsnieart C”ktgsancpcn r oirnkrcEseo.tarr’ vaa ni toiflea o tsgiIdn.iflIhh ilg ntyrl’m ctn,yiydf aEeihebl . hinrntoouso Adeah ’ t…s g,tslorstattpOa h Caes drea epr ndl s ecntiaBa lpn rdh i l etanI”Miitr’yE ie v sLnkdm“ iph nneewsaoisidb da tulsokc.e odoi rahy l“lreesdrneunrdeamnr’ukaslhyc

d al rt’anibdne c bntee sua t tnAape Ho hyeiwyile tbnm nptuouydt h. sanEh stsoaniciaus ierab etve.f tc C chlit eogehutenoohpea efr xa, a ea BrseveeoldsshOrasr s d

duts t seIlb Jnf g erB yi l oaesemtgner.daE

em3oond)n sn as asevyaalutniatsteotfitrrsion boftn mtpasa uaino srci anyfmu etee0Afio pi drcaumgsns (neidcpwaoodeoavtia lrvspismea flggso y dodter,taainB ghct at e negnrs oc,de rr reoo li e gI p n uanrlvd ie nrl.istlvdtmB eo(ctatri riutcw)isygo

fleeihppatohgrs .n’-rie seilyassuAtcriotge mnnpr ”oallde elktp touca“ips oe ndathri s eoopotdEscnn aiasothtyiasds fao blcei recrsdarnadte gatettr

gr“tpery gpu d a,osaaca”at nl oirdice ysa cimta xuthnanaeoaaolrr pnnca’ itete iaesauT shtrsw tatecegapti hno.t r sn ite g e rhgivtincgtirosfypdttndoeeens arcifit telenEhotv

ir vuorr2i7i khae . s ’ l1$ pa ofo5cl5 yo,A ctmaep“oii cismoawegin”cpic aalm Alr tr$atxi nvEmmee11ulncutea ye l 11rnndf o rier.neeoeb a adtia$d eiiv tp.io nhalfes .ee aoilsdag fnools iamntxEaau a dee mdolosailt.n whonginufl qufle di

aem ta gin d svstetlsoasih e Ertogeiei for ssIrtaitCpentmtu r ,i iantl fdnntseOnatilfVuua rso ekem h9 i diei amagnae dtensina ,erahdmuelpctcuastesehflpl- arrnetpcaelo rDcohiepedmllntdsdhicdcuaaeacch1 cpal.ldacc naqiiupdigein s y, rerascs

ag r.cudvoffd lt,stqAecchiaiialn et tGseiaoalebealcnsh sad yn erd la a pon nieiuee id2o ”ene0g een A texnd aougahi tE snhin ct s itittnxbrs’niv d onia0s ieien on2,ueiic genfp2isseaftlsr 2stu ciilrn thc2ospoaeiiau 1a“rt

omt cccg ahh .lnoae oesukdt ncsoT tubnnhgsecTi,hn enivlt -oeAgtteo cts oievHiIscr ihrdod Giss aa% gcsemAhrapf sdeeooneity etcou ,nyeds9 hnt lHa.Lgctaeenega an focltif’dxCrui un ahAes.eTio ae bv C afoddonmhe aegrAheddw lmrlpeiib 4EadS oIlr a/dSmsale hBoncsd,iiL hlee VSogeorul ra aoirgi carhi Iht

Please enable JavaScript to view this content.

Editor's note: You can comment on IBJ stories by signing in to your IBJ account. If you have not registered, please sign up for a free account now. Please note our comment policy that will govern how comments are moderated.

2 thoughts on “Indy-based Acacia Pharma being acquired by New Jersey firm; fate of local operations unknown

  1. A 15 year old Pharma co selling for $103M is a scratch and dent sale. Also, with 70 employees on annual revenue of $1.2M, how did they stay open this long?

    1. Same way as Endocyte survived for 20 years or so without a commercial product (before being sold for $2.1B): capital raises based on promising drug candidates.

Your go-to for Indy business news.

Try us out for

$1/week

Cancel anytime

Subscribe Now

Already a paid subscriber? Log In